Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations
Abstract BRAFV600E melanoma patients, despite initially responding to the clinically prescribed anti-BRAFV600E therapy, often relapse, and their tumors develop drug resistance. While it is widely accepted that these tumors are originally driven by the BRAFV600E mutation, they often eventually diverg...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-06-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-021-00190-3 |